Lilly Medicine Foundry

Lilly's $4.5 billion Medicine Foundry in Lebanon combines research with manufacturing process development and clinical-trial medicine production. It is expected to create 400 full-time jobs and target a late-2027 opening. This separately announced facility is excluded from the $9B API-and-Advanced-Therapies campus record and from the May 2026 Lebanon expansion record.

Investment
$4.50B
Permanent jobs announced
400
Status
Under Construction
Expected opening
2027
Why this project qualifies

With $4.5 billion in facility-specific investment and 400 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Eli Lilly
Industry
Pharmaceuticals
Location
Lebanon, Indiana
Investment
$4.50B
Permanent jobs announced
400
Status
Under Construction
Announced
Oct 2, 2024
Expected opening
2027
Added to tracker
Aug 30, 2026
Sources

Official references

Related

Other projects to know

Back to the tracker/projects/eli-lilly-medicine-foundry-lebanon